Besides, Sun et al. discovered that in T2DM patients the circulating VEGF-B levels decreased when treated with thiazolidinediones, which can inhibit peroxisome proliferators-activated receptor-γ activity and result in insulinresistant decrease (Sun et al., 2014[38]). This evidence concerns the gene VEGFB and type 2 diabetes mellitus.